Clinical trial
Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or…
NCT00267696 · Ohio State University Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00267696 |
|---|---|
| Title | Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
| Official title | A Phase II Study of Gemcitabine/Carboplatin/Bevacizumab in Platinum Sensitive Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients. |
| Lead sponsor | Ohio State University Comprehensive Cancer Center, Other |
| Collaborators | Genentech, Inc. Industry Eli Lilly and Company |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab, Gemcitabine, Carboplatin |
| Enrollment | 45 |
| Start date | Nov 1, 2005 |
| Primary completion | Sep 1, 2013 |
| Completion | Dec 1, 2013 |
| First posted | Dec 21, 2005 |
| Last update posted | Apr 30, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: